publication date: Jan. 10, 2020

Funding Opportunities

ALK Positive and LUNGevity issue RFA for 2020 ALK-positive Lung Cancer Research Award Program

ALK Positive/LUNGevity is requesting applications for the 2020 ALK-positive Lung Cancer Research Award. Letters of intent are due Feb. 14.

Funded projects are expected to have a direct impact on the outcomes of patients with advanced ALK-positive lung cancer, but innovative proposals that address other unmet needs in the ALK-positive lung cancer space are also invited for submission.

The ALK-positive award is open to researchers at United States and international institutions.

At the time of application, an international candidate must name a co-principal investigator who is employed at a U.S. institution.

This award is in addition to the LUNGevity Career Development Award. Information for those awards will be announced separately.

There are two award mechanisms:

Transformational Award

The successful applicant may receive up to $500,000 over an award term of two years for the Transformational Award.

Clinical Trial Innovation Award.

The successful applicant may receive up to $750,000 over an award term of two years for the Clinical Trial Innovation Award.

For complete information and instructions, visit http://www.LUNGevity.org/ALK-RFA or proposalcentral.com beginning Jan. 13, 2020. Direct any questions to Margery Jacobson at mjacobson@LUNGevity.org or 312-407-6109.

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.